Table 2.
Baseline clinical characteristics and procedural details in the overall population
| Variables | High-dose of RSV n/population (%) | Control n/population (%) |
|---|---|---|
| Number of patients | 1671/3273 (51.1 %) | 1602/3273 (48.9 %) |
| Male | 1150/1671 (68.8 %) | 1075/1602 (67.1 %) |
| Hypertension | 1088/1671 (65.1 %) | 988/1602 (61.7 %) |
| Diabetes Mellitus | 473/1671 (28.3 %) | 449/1602 (28.0 %) |
| Smoker | 592/1606 (36.9 %) | 573/1542 (37.2 %) |
| Previous MI | 223/1067 (20.9 %) | 224/1069 (21.0 %) |
| Previous PCI | 160/1019 (15.7 %) | 143/1017 (14.1 %) |
| Stable angina | 732/1671 (43.8 %) | 657/1602 (41.0 %) |
| NSTEMI | 759/1671 (45.4 %) | 759/1602 (47.3 %) |
| STEMI | 181/1671 (10.8 %) | 188/1602 (11.7 %) |
| Multi-vessel disease | 198/644 (30.7 %) | 157/633 (24.8 %) |
| B2/C lesions | 654/918 (71.2 %) | 590/855 (69.0 %) |
| Thrombus | 122/757 (16.1 %) | 135/763 (17.7 %) |
| LM | 16/700 (2.3 %) | 25/709 (3.5 %) |
| LAD | 666/1253 (53.2 %) | 619/1174 (52.7 %) |
| LCX | 360/1315 (27.3 %) | 354/1244 (28.4 %) |
| RCA | 393/1253 (31.4 %) | 368/1174 (31.3 %) |
| Multiple vessel PCI | 216/644 (33.5 %) | 203/768 (26.4 %) |
| Aspirin | 1624/1671 (97.2 %) | 1548/1602 (96.6 %) |
| Clopidogrel | 1599/1605 (99.6 %) | 1530/1536 (99.6 %) |
| β-blockers | 952/1393 (68.3 %) | 979/1402 (69.8 %) |
| ACEI/ARB | 910/1393 (65.3 %) | 953/1402 (67.9 %) |
| Glycoprotein IIb/IIIa inhibitors | 76/1025 (7.4 %) | 103/959 (10.7 %) |
| Numbers of DES | 560/696 (80.5 %) | 556/691 (80.5 %) |
Previous MI previous myocardial infarction, Previous PCI previous percutaneous coronary intervention, NSTE-ACS non-ST segment elevation acute coronary syndrome, STEMI ST segment elevation myocardial infarction, LM, left main, LAD left anterior descending, LCX left circumflex, RCA right coronary artery, DES drug-eluting stent